Antagonist Development Service for Cancer Immunotherapy
Immuno-oncology Antagonist
Immunomodulators are a class of drugs that can regulate the function of the immune system, and are used for a series of immune-related diseases, such as autoimmune diseases, organ transplant rejection, etc., by suppressing or enhancing the activity of the immune system. Creative Biolabs offers a range of services related to immune antagonists, including synthesis and design, biomarker testing, in vitro and in vivo evaluation, and more to provide a solid theoretical basis for your cancer immunology research.
Glutamine and Arginine Metabolism Antagonist
Kynurenine Pathway Antagonist
ENPP1, TREX1and PARP7 Antagonist
Our Service
A great deal of research and design is required before an immune antagonist can be synthesized. The approximate synthetic route of the immune antagonist is shown in the figure below:
Fig.1 Synthesis of immune antagonists.
Assessing and regulating pathway-related biomarkers may predict response to tumor immunotherapy. Creative Biolabs offers assays for the following immuno-related markers of oncology:
|
Method
|
Objective
|
|
PD-L1 expression level, tumor mutational burden (TMB), microsatellite instability
|
Screening for optimal immunotherapy outcomes
|
|
Expression profiling of inflammatory genes in dendritic cells or tumor-infiltrating lymphocytes and T cells
|
To predict response to immunotherapy drugs
|
|
Correlation of peripheral blood with TME PD response
|
To provide a suitable immunotherapy solution
|
|
Tumor RNA gene expression evaluation
|
For immune activation and cytokine assessment
|
|
Tumor tissue DNA evaluation
|
For the evaluation of TMB and tumor immunogenicity
|
|
Expression of tumor PD-L1 on tumors and immune cells
|
For comparison at baseline and in treatment
|
-
In Vitro Evaluation
-
Immune parameter assessment
-
Molecular mechanistic assessment
-
Safety assessment
-
Tumor immune microenvironment analysis
-
And so on
Choosing the right animal model is critical for preclinical trials, and Creative Biolabs can offer several common models:
|
Type
|
Advantage
|
Disadvantage
|
Application
|
|
isogenic mouse
|
It can stably express luciferase groups and is easy to use.
|
Tumors originate from mice and do not directly match human disease, so they are not a good predictor of clinical outcomes.
|
Suitable for screening large numbers of drug candidates.
|
|
Transgenic/Genetically Engineered Mouse Models (GEMMs)
|
The disease progresses more naturally.
|
Mutations in transgenic models limit neoantigen production and are less suitable for immuno-oncology studies
|
Study the function of specific genes and disease mechanisms.
|
|
Cell-derived xenograft model (CDX)
|
In the construction of tumor cell lines, the tumorigenesis rate is high, the modeling time is short, the reproducibility is good, the cost is low, and fluorophores can be added.
|
Tumors are cultured in vitro and lack a human-derived tumor growth environment. Immunodeficient mice need to be selected for construction, which is not fully suitable for studying the role of the immune system in tumor development.
|
Conduct preclinical pharmacodynamics testing, PK/PD correlation and combination therapy studies.
|
|
Patient-derived xenograft model (PDX)
|
Heterogeneous tumors that follow the effects of human primary tumor resistance and TEM on drugs, preserving the genetic characteristics of patients.
|
Some models are difficult to build and grow at a slower rate than CDX.
|
Targeted reagent R&D and production, personalized therapy R&D.
|
|
Humanized mouse/immune stand-in model
|
Partial human immune system with human drug targets that allow the study of human cancer cell lines or primary patient-derived tumors in the context of autologous or xenoimmunology.
|
The immune system is suboptimal, and human xenogeneic inhibitor versus host disease is common.
|
To investigate the efficacy of murine homologous or alternative antibodies, as well as aspects of the human immune response in mouse models
|
|
Tumor organoids
|
Similar to the original tumor, it is a more clinically relevant model for preclinical research.
|
Lack of key components in TME.
|
Drug screening and prediction of efficacy to a certain extent; Avoid medication side effects.
|
If you are interested in agonist development services for cancer immunotherapy, you can click here for more information!
For Research Use Only | Not For Clinical Use
Download our brochure